Chuzhou

Researchers are establishing a standardized clinical database for patients with liver cancer, including hepatocellular carcinoma and related types, to support high-quality real-world clinical studies. This observational study is led by the Department of Hepatobiliary Surgery at the First Affiliated Hospital of the University of Science and Technology of China USTC in collaboration with multiple centers nationwide. The purpose is to collect detailed clinical information to better understand liver cancer outcomes over time. Participants will receive routine clinical treatments for liver cancer, such as surgical resection, ablation, transarterial chemoembolization TACE, hepatic arterial infusion chemotherapy HAIC, and various anti-tumor drugs including immunologic, targeted, and chemotherapy agents. The study observes and records these standard treatments without assigning interventions. The research will track these patients in a cohort database to monitor their treatment and progression. During the study, participants will be followed for up to 10 years to assess overall survival, recurrence-free survival, and survival time after cancer recurrence. Researchers will collect blood and surgical tissue samples and perform regular follow-up visits to gather clinical data and pathology results. This long-term monitoring aims to provide comprehensive insights into liver cancer progression and treatment outcomes.

Researchers are studying the safety and effectiveness of early use of tirofiban in patients who have acute ischemic stroke and are treated with tenecteplase. This study is exploring whether adding tirofiban soon after tenecteplase can reduce the risk of blood clot re-blockage in the brain, which happens in some patients after initial treatment. The study is a phase 3 trial aiming to improve stroke outcomes by preventing this reocclusion. Participants first receive tenecteplase intravenously for stroke treatment. Those who meet the study criteria are then randomly assigned to receive either tirofiban or a placebo. Tirofiban or placebo is given intravenously starting as soon as possible after randomization, initially as a higher dose for 30 minutes, followed by a continuous lower dose infusion for nearly 48 hours. After 24 hours, patients receive aspirin andor clopidogrel or their placebos, then after 44 hours, antiplatelet therapy with aspirin andor clopidogrel continues until the 90-day follow-up. During the study, participants undergo assessments including neurological exams and monitoring for bleeding or other adverse events. The main outcome measured is excellent functional recovery 90 days after randomization. Other outcomes include disability levels, neurological improvement, quality of life, bleeding events, and mortality. Safety and serious adverse events are tracked through the 90-day period to evaluate treatment effects and risks.

Researchers are investigating whether local radical treatment of liver metastases combined with systemic therapy can improve outcomes in patients with colorectal cancer that has spread to multiple organs. The study aims to determine if this approach can benefit survival compared to systemic therapy alone or combined with other local interventions. It also explores risk factors affecting prognosis, assesses quality of life, and evaluates treatment safety. Participants are assigned based on their preference to one of two groups. One group receives radical local treatment of liver metastases through surgery or ablation combined with systemic therapy, which includes chemotherapy, targeted drugs, or immunotherapy. The other group receives systemic therapy alone or combined with local interventional therapies such as transcatheter arterial chemoembolization TACE or hepatic arterial infusion chemotherapy HAIC. Participants will be followed every three months for up to two years. During this time, researchers will monitor overall survival, progression-free survival focused on liver metastases, and any adverse events. Quality of life will be assessed using questionnaires. Regular evaluations will include clinical assessments and laboratory tests to ensure safety and track outcomes throughout the study period.

Researchers are evaluating the efficacy and safety of TQB2102 for injection in adults aged 18 to 75 years with HER2 negative recurrent or metastatic breast cancer. This Phase II trial focuses on patients whose cancer has returned or spread and who are not suitable for surgery or radiation aimed at cure. Participants must have measurable tumors and meet certain health standards to join the study. Participants receive TQB2102 for injection, a HER2 dual-antibody-drug conjugate, given as an intravenous infusion at a dose of 7.5 mgkg every three weeks, with each treatment cycle lasting 21 days. The study follows participants for up to 48 months to assess various outcomes including tumor response, disease control, survival, and safety. Blood samples are collected at specific treatment cycles to monitor anti-drug antibodies. During the study, participants will undergo evaluations of tumor response and progression, survival, and adverse events. Safety is monitored throughout, including tests for anti-drug antibodies and circulating tumor DNA. Female participants of childbearing potential agree to use contraception during and after the study, and all participants are monitored for organ function and disease status. Follow-up continues up to four years to fully assess treatment effects and safety.

This research aims to evaluate the effect of two different treatments on gastrointestinal bleeding in patients with acute coronary syndrome ACS who have undergone percutaneous coronary intervention PCI and require dual antiplatelet therapy DAPT for at least six months. The study focuses on patients infected with Helicobacter pylori Hp, a known risk factor for gastrointestinal bleeding, which occurs commonly in these patients. Experts in China have recommended Hp detection and eradication therapy alongside DAPT, but evidence is lacking. This trial investigates whether Vonoprazan-based dual eradication therapy is not inferior to standard proton pump inhibitor PPI treatment in preventing bleeding events. The study enrolls 2600 patients randomized into two groups. One group receives a 14-day dual eradication therapy with Vonoprazan 20 mg twice daily and amoxicillin 1 g three times daily, followed by monitoring for six months. The other group receives pantoprazole 40 mg daily for six months as the control treatment. All patients continue their DAPT regimen, which includes aspirin and either clopidogrel or ticagrelor, as decided by their doctors. Hp infection is confirmed before enrollment using breath tests and antibody detection. Participants will be closely monitored throughout the six-month follow-up period. Assessments include repeat Hp testing after treatment completion and tracking any gastrointestinal bleeding or major cardiovascular events. Safety visits record any adverse reactions or incomplete treatments. The primary outcome measured is the incidence of gastrointestinal bleeding over six months, with additional outcomes including cardiovascular events and complex gastrointestinal events. This comprehensive monitoring aims to provide clear evidence on managing Hp infection in ACS patients undergoing DAPT.